StockData

Sanara MedTech vs Xtant Medical

SMTI and XTNT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SMTI and XTNT compare

Sanara MedTech is the larger company, worth 10 times as much as Xtant Medical ($301M against $29.4M).

Sanara MedTech grew revenue faster over the last twelve months (13.0% versus −14.3% for Xtant Medical).

Xtant Medical keeps more of each dollar of sales as profit, with a net margin of −10.2% compared with −29.2% at Sanara MedTech.

Xtant Medical scores higher on the StockData Score (9 against 6 for Sanara MedTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSMTIXTNT
Size and price
Market cap$301M$29.4M
Share price$32.76$0.210
Change, 1 year67.1%−68.2%
Change, 5 years14.3%−73.2%
Beta (5Y)1.430.07
Employees108151
StockData Score
Total score69 (better)
Valuation score03 (better)
Growth score3 (better)1
Performance score12 (better)
Health score23 (better)
Dividend score00
Valuation
P/S2.7×0.3× (better)
P/B37.9×0.7× (better)
EV/EBITDA30.5×–
P/FCF66.8×–
FCF yield1.5% (better)−2.4%
Fair value$13.59$1.03
Margin of safety−141%79.7% (better)
Growth
Revenue growth (TTM)13.0% (better)−14.3%
Revenue growth, 5Y average45.9% (better)20.2%
Profitability
Gross margin93.0% (better)59.4%
Operating margin7.7% (better)−9.6%
Net margin−29.2%−10.2% (better)
FCF margin4.1% (better)−0.64%
Return on equity−148%−25.2% (better)
Return on invested capital13.1% (better)−15.8%
Financial health
Debt / equity5.850.28 (better)
Net debt / EBITDA2.85–
Interest coverage1.2× (better)−3.8×
Current ratio2.58 (better)2.16
Altman Z-score3.77 (better)−2.78
Piotroski F-score38 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions19.4%106%
Held by insiders14.9%–
Short interest, % of float5.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.